WuXi PharmaTech Co., Ltd. Announces Appointment Of Dr. Hua Mu To Head Product Development Service And Partnership Business Unit

SHANGHAI, Feb. 26, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that Dr. Hua Mu has joined WuXi as Senior Vice President of Operations and Global Head of the Product Development Service and Partnership Business Unit, reporting to Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

Dr. Mu has over 18 years of clinical research and development experience, having held medical and clinical leadership positions with several global pharmaceutical and biotech companies, including Roche, Abraxis Bioscience (now Celgene), Biogen Idec, Genentech, and Procter and Gamble. Dr. Mu's responsibilities have included early- to late-stage development of cytotoxic agents, small molecules, and monoclonal antibodies; management of clinical and regulatory organizations; creation and oversight of external collaborations and partnerships; interaction with regulatory authorities in the United States, Europe and Asia; and advancement of drug candidates to market and through their post-market development.

Before joining WuXi, Dr. Mu was the Executive Vice President and Chief Medical Officer at Hutchison MediPharma, a company that in four years has successfully obtained five IND approvals and one Phase II/III CTA approval from the China Food and Drug Administration and advanced six compounds into various stages of clinical development. Dr. Mu received his medical degree from West China University of Medical Sciences and a Ph.D. in epidemiology from the University of California at Berkeley, under the mentorship of Dr. Mary-Claire King, a renowned cancer geneticist and the discoverer of the breast cancer BRCA gene. Earlier in his career, Dr. Mu was a Senior Fellow at the Schools of Medicine of the University of California in San Francisco and the University of Washington, where he conducted translational research on autoimmune diseases and breast cancer.

"I am delighted to welcome Hua to WuXi's leadership team," said Dr. Li. "Hua brings extensive experience, particularly in clinical development in China, that is very critical for WuXi to help our partners bring their innovations to China and to develop innovative drugs to benefit Chinese patients."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
Tel: +1-201-585-2048
Email: [email protected]

Aaron Shi,
Associate Director, Corporate Communications
Tel: +86-21-5046-4362
Email: [email protected]

SOURCE WuXi PharmaTech